Alex Gorsky - Johnson Johnson Chairman of the Board, CEO
| JNJ Stock | EUR 139.48 0.16 0.11% |
Chairman
Mr. Alex Gorsky is Chairman of the Board, Chief Executive Officer of Directors of the Company. He was appointed as Chairman, Board of Directors in December 2012. He was named Chief Executive Officer, Chairman of the Executive Committee and joined the Board of Directors in April 2012. Mr. Gorsky began his Johnson Johnson career with Janssen Pharmaceutica Inc. in 1988. Over the next 15 years, he advanced through positions of increasing responsibility in sales, marketing, and management. In 2001, Mr. Gorsky was appointed President of Janssen Pharmaceutical Inc., and in 2003 he was named Company Group Chairman of the Johnson Johnson pharmaceutical business in Europe, the Middle East and Africa. Mr. Gorsky left Johnson Johnson in 2004 to join Novartis Pharmaceuticals Corporationrationration, where he served as head of the companys pharmaceutical business in North America. Mr. Gorsky returned to Johnson Johnson in 2008 as Company Group Chairman for Ethicon. In early 2009, he was appointed Worldwide Chairman of the Surgical Care Group and member of the Executive Committee. In September 2009, he was appointed Worldwide Chairman of the Medical Devices and Diagnostics Group. Mr. Gorsky became Vice Chairman of the Executive Committee in January 2011. Mr. Gorsky also serves on the boards of the Travis Manion Foundation, the Congressional Medal of Honor Foundation, the National Academy Foundation, and the Wharton Board of Overseers. He is also a member of the Board of Directors of the Business Roundtable and serves as the Chairman of its Corporationrationrate Governance Committee. since 2012.
| Age | 57 |
| Tenure | 12 years |
Similar Executives
| Found 2 records | CHAIRMAN Age | ||
| David Meyer | Titan Machinery | 70 | |
| Dale Corman | Western Copper and | N/A | |
Johnson Johnson Leadership Team
Elected by the shareholders, the Johnson Johnson's board of directors comprises two types of representatives: Johnson Johnson inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Johnson. The board's role is to monitor Johnson Johnson's management team and ensure that shareholders' interests are well served. Johnson Johnson's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Johnson Johnson's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jennifer Doudna, Independent Director | ||
| Alex Gorsky, Chairman of the Board, CEO | ||
| William Perez, Independent Director | ||
| Michael Sneed, Executive Vice President - Global Corporate Affairs and Chief Communication Officer | ||
| Marillyn Hewson, Independent Director | ||
| Jorge Mesquita, Executive Vice President Worldwide Chairman - Consumer | ||
| Mary Coleman, Independent Director | ||
| Michael Ullmann, Vice President General Counsel | ||
| Joaquin Duato, Executive Vice President Worldwide Chairman - Pharmaceuticals | ||
| Kathy Wengel, Executive Vice President Chief Global Supply Chain Officer | ||
| Jennifer Taubert, Executive Vice President - Worldwide Chairman, Pharmaceuticals | ||
| Mary Beckerle, Director | ||
| Sandra Peterson, Group Worldwide Chairman | ||
| Scott Davis, Director | ||
| Louise Mehrotra, Vice President Investor Relations | ||
| Ashley McEvoy, Executive Vice President - Worldwide Chairman, Medical Devices | ||
| Ronald Williams, Independent Director | ||
| Kathryn Wengel, Executive Vice President Chief Global Supply Chain Officer | ||
| Anne Mulcahy, Lead Independent Director | ||
| Joseph Wolk, Vice President - Investor Relations | ||
| Thibaut Mongon, Executive Vice President Worldwide Chairman, Consumer | ||
| Ian Davis, Independent Director | ||
| Paulus Stoffels, Chief Scientific Officer, Worldwide Chairman - Pharmaceuticals Group | ||
| Mark McClellan, Independent Director | ||
| Charles Prince, Independent Director | ||
| Eugene Washington, Independent Director | ||
| Dominic Caruso, CFO, Vice President - Finance | ||
| Peter Fasolo, Vice President - Global Human Resources | ||
| Susan Lindquist, Independent Director |
Johnson Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Johnson Johnson a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Current Valuation | 443.95 B | |||
| Price To Book | 6.27 X | |||
| Price To Sales | 4.97 X | |||
| Revenue | 94.94 B | |||
| EBITDA | 28.97 B | |||
| Net Income | 17.94 B | |||
| Total Debt | 26.89 B | |||
| Cash Flow From Operations | 21.19 B | |||
| Price To Earnings To Growth | 3.86 X | |||
| Number Of Employees | 29 |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Johnson Johnson. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For more information on how to buy Johnson Stock please use our How to Invest in Johnson Johnson guide.You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Complementary Tools for Johnson Stock analysis
When running Johnson Johnson's price analysis, check to measure Johnson Johnson's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Johnson Johnson is operating at the current time. Most of Johnson Johnson's value examination focuses on studying past and present price action to predict the probability of Johnson Johnson's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Johnson Johnson's price. Additionally, you may evaluate how the addition of Johnson Johnson to your portfolios can decrease your overall portfolio volatility.
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |